Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Merck Halts Enrollment in Keytruda Clinical Trials Following Patient Deaths

XTALKS VITALS NEWS

Chemo

The decision was made based on an external data monitoring committee’s recommendation.

Share this!

June 15, 2017 | by Sarah Hand, M.Sc.

Merck has announced that they will not be enrolling any new patients into two Phase III clinical trials involving Keytruda (pembrolizumab) following reports of patient deaths. The decision was made based on an external data monitoring committee’s recommendation.

“The pause is to allow for additional information to be collected to better understand more reports of death in the Keytruda groups,” said Merck in a press release. “Patients currently enrolled in these two studies will continue to receive treatment.”

Both the KEYNOTE-183 and KEYNOTE-185 clinical trials were testing Keytruda treatment in combination with other therapies in patients with multiple myeloma. Keytruda has already been approved for a number of indications, including treatment of melanoma, lung cancer and Hodgkin lymphoma.



The KEYNOTE-183 clinical trial is assessing a combo treatment involving pomalidomide, low-dose dexamethasone and Keytruda. In addition to low-dose dexamethasone, the KEYNOTE-185 clinical trial is testing a combo of lenalidomide and Keytruda.

Keytruda is an anti-PD-L1 immunotherapy that supports the patient’s immune system in destroying cancer cells. The checkpoint inhibitor has not shown these types of safety issues in previous clinical trials.

The FDA recently approved Keytruda to treat patients whose cancer has the MSI-H biomarker, regardless of the tumor’s tissue of origin. The biomarker has been identified in multiple cancer types, including endometrial, colorectal and gastrointestinal tumors.


Keywords:  Clinical Trial, Keytruda, Multiple Myeloma


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.